Research published by Stefanski et al in Blood Advances sought to determine the effect of varying doses of tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy, across the approved dosing range on survival outcomes in pediatric patients with B-cell acute lymphoblastic leukemia (ALL).
